Fusion proteins comprising enzyme replacement therapy enzymes
Inventors
Henry, Anastasia • Kariolis, Mihalis S. • Mahon, Cathal S. • Silverman, Adam P. • SRIVASTAVA, Ankita • ULLMAN, Julie
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Provided herein are fusion proteins that comprise an enzyme replacement therapy enzyme and an Fc region, as well as methods of using such proteins to treat a lysosomal storage disorder. Methods for transporting agents across the blood-brain barrier are also provided herein.
Core Innovation
The independent claims describe methods of treating Hunter syndrome by administering a protein comprising an iduronate 2-sulfatase (IDS) amino acid sequence linked to a first Fc polypeptide and a second Fc polypeptide. The protein is defined by sequence identity requirements, specified sequence features, and the capability of the second Fc polypeptide to specifically bind to a transferrin receptor to promote transport across the blood-brain barrier. The constructs encompass engineered Fc polypeptides, heterodimerization, and hinge or linker arrangements that exhibit retained IDS activity and cellular substrate clearance.
The disclosure describes applications to Hunter syndrome and related enzyme replacement therapy fusion embodiments for lysosomal storage disorders. Documented findings evaluate protein characterization, transferrin receptor binding, improved brain uptake, and reduced brain glycosaminoglycan levels in cellular and animal models. Background problem definitions, abstract text, and operational procedural details are omitted from the provided text.
Claims Coverage
The provided claims identify three independent claims covering methods of treating Hunter syndrome by administering a protein comprising an IDS–Fc fusion polypeptide and a second Fc polypeptide, with differing sequence and residue limitations.
IDS–Fc fusion with a transferrin-receptor-binding Fc polypeptide
The claim covers administering a protein comprising an IDS amino acid sequence linked to the N-terminus of a first Fc polypeptide, with the IDS sequence having at least 90% identity to SEQ ID NO: 92, and a second Fc polypeptide having at least 90% identity to SEQ ID NO: 151 and capable of specifically binding to a transferrin receptor.
Specified IDS–Fc fusion with a residue-defined second Fc polypeptide
The claim covers administering a protein comprising a fusion polypeptide with SEQ ID NO: 235 and a second Fc polypeptide having at least 90% identity to SEQ ID NO: 151, with specified amino acids at defined positions.
IDS–Fc fusion with an eight-residue-defined second Fc polypeptide
The claim covers administering a protein comprising an IDS amino acid sequence linked to the N-terminus of a first Fc polypeptide, with the IDS sequence having at least 90% identity to SEQ ID NO: 92, and a second Fc polypeptide having at least 90% identity to SEQ ID NO: 151 and eight specified residues at designated positions.
Together, the three independent claims cover methods of treating Hunter syndrome using an administered protein combining an IDS–Fc fusion with a second Fc polypeptide, distinguished by sequence identity thresholds, specific fusion sequences, transferrin-receptor binding, and structural residue modifications.
Stated Advantages
The transferrin receptor-binding Fc polypeptide promotes transport across the blood-brain barrier, providing increased brain exposure and uptake.
The described constructs retain IDS activity and support cellular substrate clearance.
The constructs provide reduced glycosaminoglycan levels in brain tissue in animal models of IDS deficiency.
Documented Applications
Treatment of Hunter syndrome in a subject in need thereof using an IDS–Fc fusion protein paired with a transferrin receptor-binding Fc polypeptide.
Treatment of other lysosomal storage disorders, including enzyme replacement therapy fusion embodiments such as SGSH and ASM fusions.
Interested in licensing this patent?